Jeena Cho will cover resilience, work/life integration, and wellness in the workplace. Her area of expertise includes women’s issues, diversity, wellness, productivity, mindfulness, and meditation. Richard Carlton will be covering substance abuse and depression disorders. He will dive into the relation between practicing law and the mentality necessary to "succeed" at practicing law.
Panelists will discuss how cannabis use and substance abuse issues can interfere with an attorney’s competence obligations, and mandatory reporting requirements.
Of all white collar professionals in the United States, alcoholism and depression are most common among lawyers. And we serve an industry that makes an intoxicant more widely available than it has ever historically been. So, what does that mean for our own mental health and our own battles with substance abuse.
Join us for a discussion of patents, patent rights, limitations of patents, and alternatives for protection, from utility to Plant Patents and PVP. Additionally, the panel will delve into deposit requirements (availability to 3rd parties and timing of deposit), data- quality, scope (written description/enablement), and the dynamics for Plant Patent-Flexibility and data quality requirements, and patent enforcement.
Niall will discuss cannabis jurisdiction, legislation, regulation, Medical Cannabis Access Programme (MCAP, the Specified Controlled Drugs (Cannabis-Based Medical Products), indications, CBD - Novel Foods (Conflict of Laws), and adult use in the Republic of Ireland.
This panel seeks to address the pathways for federal cannabis reform in the 117th
Congress, considering legislative vehicles, political pragmatism, and actions of the
Administration.
In this 90-minute program, panelists will discuss a range of topics related to the interstate commerce ban, including licensee residency requirements adopted in many states (and associated litigation); the Dormant Commerce Clause; economic and social equity implications of closed markets; and the possibility of interstate compacts as a stopgap pending federal legalization. Speakers will also address the ban’s impact on medical patients and how pending legislation and post-legalization regulatory schemes may impact licensed operators and other industry participants.
The purpose of this webinar is to provide a clear overview of the current regulatory landscape in France on both medical cannabis and wellness hemp/CBD and to answer some frequently asked questions in order to provide some practical tips as to what can be done or not and what to expect in the near future.